www.taro.com

Trademarks and Copyright© The images and information contained in the Site are, to the fullest extent possible, copyrighted and otherwise proprietary. It is the policy of Taro to enforce its intellectual property rights to the fullest extent of the law, including (where applicable) seeking criminal sanctions.


2005
 
DateTitle
December 29, 2005
Taro And Alkem To Collaborate On Product Development For U.S. And Other Markets
November 17, 2005
Taro Reports Third Quarter and Nine Month 2005 Results
November 8, 2005
Taro to Report Third Quarter 2005 Results and Conduct Conference Call on November 17, 2005
October 26, 2005
Taro to Initiate Phase III Clinical Trial in the U.S. of Novel Ovide® Formulation for Control of Head Lice
September 23, 2005
Taro Receives Approval For Mupirocin Ointment USP, 2% ANDA: Generic Equivalent to Bactroban Ointment
September 16, 2005
Taro Receives FDA Approval for Alclometasone Dipropionate Cream USP, 0.05% ANDA; Tentative ANDA Approval Received for Gabapentin Capsules in 3 Strengths
August 10, 2005
Taro Receives Approval for Ciclopirox Topical Suspension USP, 0.77% ANDA; Generic Equivalent to Loprox® Topical Suspension, 0.77%
August 5, 2005
Taro Receives Approval for Halobetasol Propionate Cream, 0.05% ANDA; Generic Equivalent to Ultravate® Cream
August 4, 2005
Taro Receives Approval for Hydrocortisone Butyrate Cream USP, 0.1% ANDA; Generic Equivalent to Locoid® Cream
April 26, 2005
Taro Reports Financial Results for the Company's 1st Quarter, ended March 31, 2005
April 20, 2005
Taro to Report First Quarter 2005 Results and Conduct Conference Call on April 26, 2005
April 14, 2005
Taro Receives Approval for Ciclopirox Olamine Cream USP, 0.77%

Generic Equivalent to Loprox(R) Topical Cream

March 3, 2005
Taro to divest ElixSure® and Kerasal® OTC products to Alterna under exclusive license
March 2, 2005
Taro Receives Approval for Miconazole Nitrate Vaginal Cream, 4% ANDA
February 24, 2005
Taro Reports 4th Quarter and Full Year 2004 Results
January 20, 2005
Taro Receives Approval for Terconazole Vaginal Cream, 0.4% ANDA; Generic Equivalent to Terazol-R- 7 Vaginal Cream
Privacy Statement   |   Terms of Use   |   Safe Harbor Statement